Your browser doesn't support javascript.
loading
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman, Michael S; Lawrentschuk, Nathan; Francis, Roslyn J; Tang, Colin; Vela, Ian; Thomas, Paul; Rutherford, Natalie; Martin, Jarad M; Frydenberg, Mark; Shakher, Ramdave; Wong, Lih-Ming; Taubman, Kim; Ting Lee, Sze; Hsiao, Edward; Roach, Paul; Nottage, Michelle; Kirkwood, Ian; Hayne, Dickon; Link, Emma; Marusic, Petra; Matera, Anetta; Herschtal, Alan; Iravani, Amir; Hicks, Rodney J; Williams, Scott; Murphy, Declan G.
Afiliación
  • Hofman MS; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: michael.hofman@petermac.org.
  • Lawrentschuk N; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Surgery, Austin Health, Melbourne, VIC, Australia; Urological Society of Australia and New Zealand, NSW, Australia.
  • Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; University of Western Australia, Faculty of Health and Medical Sciences, Perth, WA, Australia; ARTnet, NSW, Australia.
  • Tang C; Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, Australia.
  • Vela I; Department of Urology, Princess Alexandra Hospital, Australian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Translational Research Institute, Brisbane, QLD, Australia.
  • Thomas P; Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Rutherford N; Department of Nuclear Medicine, Hunter New England Health, Newcastle, NSW, Australia.
  • Martin JM; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
  • Frydenberg M; Department of Surgery, Monash University and Cabrini Institute, Cabrini Health, Melbourne, VIC, Australia.
  • Shakher R; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia.
  • Wong LM; Department of Urology and Surgery, St Vincent's Health Melbourne, University of Melbourne, Melbourne, VIC, Australia.
  • Taubman K; Department of Medical Imaging, PET/CT and St Vincent's Private Radiology, St Vincent's Health, Melbourne, VIC, Australia.
  • Ting Lee S; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia.
  • Hsiao E; University of Sydney, Department of Nuclear Medicine and PET, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Roach P; University of Sydney, Department of Nuclear Medicine and PET, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Nottage M; Clinical and Research Imaging Centre, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Dr Jones and Partners Medical Imaging, Adelaide, SA, Australia.
  • Kirkwood I; Department of Nuclear Medicine and PET, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.
  • Hayne D; UWA Medical School, University of Western Australia, Perth, WA, Australia.
  • Link E; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Marusic P; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Matera A; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Herschtal A; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Iravani A; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Hicks RJ; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Williams S; Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, NSW, Australia.
  • Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Lancet ; 395(10231): 1208-1216, 2020 04 11.
Article en En | MEDLINE | ID: mdl-32209449

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Glutamato Carboxipeptidasa II / Imagen de Cuerpo Entero / Tomografía Computarizada por Tomografía de Emisión de Positrones / Antígenos de Superficie Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Glutamato Carboxipeptidasa II / Imagen de Cuerpo Entero / Tomografía Computarizada por Tomografía de Emisión de Positrones / Antígenos de Superficie Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2020 Tipo del documento: Article